Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

FDA Considers Splitting Jynneos Vaccine Into Fifths for Monkeypox
FDA Considers Splitting Jynneos Vaccine Into Fifths for Monkeypox
The FDA is looking into possibly splitting doses of Bavarian Nordic’s Jynneos vaccine into fifths to inoculate individuals 18 years and older against monkeypox in order to address inadequate supp...
FDA Declines Travere’s Second Attempt at Accelerated Approval for Sparsentan
FDA Declines Travere’s Second Attempt at Accelerated Approval for Sparsentan
The FDA has rejected Travere Therapeutics’ application for accelerated approval of its investigational drug sparsentan for treatment of patients with focal segmental glomerulosclerosis, a rare d...
Eli Lilly to Make Bebtelovimab Commercially Available
Eli Lilly to Make Bebtelovimab Commercially Available
Eli Lilly said it will make its COVID-19 drug bebtelovimab commercially available to U.S. states and territories, hospitals and other providers later this month. ...
Civica Launches Its First Lower-Cost Generic Drug
Civica Launches Its First Lower-Cost Generic Drug
Civica, a nonprofit created by hospital groups to help lower generic drug prices, has launched its first product, abiraterone acetate, a prostate cancer treatment. ...
AnHeart Therapeutics Receives FDA Breakthrough Therapy Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
AnHeart Therapeutics Receives FDA Breakthrough Therapy Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
AnHeart Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational ROS-1 inhibitor taletrectinib for th...
VAX-24 Pneumococcal Vaccine Receives FDA Fast Track Designation
VAX-24 Pneumococcal Vaccine Receives FDA Fast Track Designation
California-based Vaxcyte, Inc. today announced that the U.S. FDA granted Fast Track designation to VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prev...
FDA Issues 48 Product-Specific Guidances for Generic Drug Development
FDA Issues 48 Product-Specific Guidances for Generic Drug Development
The FDA has issued 29 new draft and 19 revised draft product-specific guidances meant to foster generic drug development and Abbreviated New Drug Application (ANDA) approvals. ...
VIVJOA (oteseconazole) to Treat Recurrent Vulvovaginal Candidiasis, USA
VIVJOA (oteseconazole) to Treat Recurrent Vulvovaginal Candidiasis, USA

VIVJOA is the first and only FDA-approved drug for the treatment of recurrent vulvovaginal candidiasis (RVVC) in females.

Ipsen’s Onivyde Failed to Meet Primary Endpoint in SCLC Phase 3 Study
Ipsen’s Onivyde Failed to Meet Primary Endpoint in SCLC Phase 3 Study
Ipsen’s Onivyde (irinotecan liposomal injection) failed to meet the primary endpoint of overall survival in phase 3 study investigating the drug in participants with small cell lung cancer (SCLC...
European Commission Orders HIPRA’s COVID-19 Vaccine
European Commission Orders HIPRA’s COVID-19 Vaccine
The European Commission has inked a procurement deal with Spain-based biotech company HIPRA for up to 250 million doses of its COVID-19 vaccine of behalf of EU members states. ...
Axcella’s Investigational Drug Shows Promise in Long COVID Clinical Trial
Axcella’s Investigational Drug Shows Promise in Long COVID Clinical Trial
Axcella Therapeutics’s investigational drug AXA1125 showed promising results in a phase 2a study involving fatigue that persists long after COVID-19 infections. ...
FDA Approves Arcutis’ Zoryve for Plaque Psoriasis
FDA Approves Arcutis’ Zoryve for Plaque Psoriasis
The FDA has approved Arcutis Biotherapeutics’ Zoryve (roflumilast) cream 0.3 percent for treatment of patients 12 years and older with plaque psoriasis and in intertriginous psoriasis — a type...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand